MOG and viral encephalitis: Regardless of whether a patient first presents with clinical symptoms of anti-NMDAR encephalitis or anti-MOG IDDs, if a patient develops new impairments during the course of immunity-regulating therapies, the potential co-occurrence of these two types of diseases must be considered.